A Phase 2, Open-label, Multicenter Study of the Safety and Efficacy of TAK-007 in Adult Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Description

This study has 2 parts. The main aim of Part 1 is to check for side effects from TAK-007 in adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma. The main aim of Part 2 is to learn if lymphomas are reduced or gone after treatment withTAK-007 in adults with relapsed or refractory B-cell Non-Hodgkin Lymphoma or indolent non-Hodgkin lymphoma (iNHL). Participants will receive lymphodepleting chemotherapy for 3 days before receiving a single injection of TAK-007. After this, participants will regularly visit the clinic for check-ups.

Resources and Links

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT05020015